成人急性淋巴细胞白血病的免疫疗法：单克隆抗体的作用
Immunotherapy in adult acute lymphoblastic leukemia: the role of monoclonal antibodies.
作者信息
Jabbour Elias, Kantarjian Hagop
机构信息
Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX.
出版信息
Blood Adv. 2016 Dec 27;1(3):260-264. doi: 10.1182/bloodadvances.2016000042.
Abstract
This article has a companion Counterpoint by Davis and Mackall. Join in the discussion of these articles at Community Conversations.
摘要
本文有一篇由戴维斯和麦考尔撰写的观点对立文章。请在“社区对话”中参与对这些文章的讨论。
相似文献
1
Immunotherapy in adult acute lymphoblastic leukemia: the role of monoclonal antibodies.成人急性淋巴细胞白血病的免疫疗法：单克隆抗体的作用
Blood Adv. 2016 Dec 27;1(3):260-264. doi: 10.1182/bloodadvances.2016000042.
2
Immunotherapy for acute lymphoblastic leukemia: from famine to feast.急性淋巴细胞白血病的免疫疗法：从匮乏到富足。
Blood Adv. 2016 Dec 27;1(3):265-269. doi: 10.1182/bloodadvances.2016000034.
3
ATG in allogeneic stem cell transplantation: standard of care in 2017? Counterpoint.异基因干细胞移植中的抗胸腺细胞球蛋白：2017年的治疗标准？反对观点。
Blood Adv. 2017 Mar 28;1(9):573-576. doi: 10.1182/bloodadvances.2016001552.
4
Related haploidentical donors are a better choice than matched unrelated donors: Counterpoint.相关单倍型相合供体比匹配的无关供体是更好的选择：反对观点。
Blood Adv. 2017 Feb 14;1(6):401-406. doi: 10.1182/bloodadvances.2016002188.
5
Platelets and hemostasis: a new perspective on an old subject.血小板与止血：一个古老主题的新视角。
Blood Adv. 2016 Nov 22;1(1):5-9. doi: 10.1182/bloodadvances.2016000059. eCollection 2016 Nov 29.
6
Should minimal residual disease negativity be the end point of myeloma therapy?微小残留病阴性应成为骨髓瘤治疗的终点吗？
Blood Adv. 2017 Mar 14;1(8):517-521. doi: 10.1182/bloodadvances.2016000117.
7
ATG in allogeneic stem cell transplantation: standard of care in 2017? Point.异基因干细胞移植中的抗胸腺细胞球蛋白：2017年的治疗标准？观点。
Blood Adv. 2017 Mar 28;1(9):569-572. doi: 10.1182/bloodadvances.2016001560.
8
Related haploidentical donors are a better choice than matched unrelated donors: Point.相关的单倍体相合供体比匹配的无关供体是更好的选择：观点。
Blood Adv. 2017 Feb 14;1(6):397-400. doi: 10.1182/bloodadvances.2016002196.
9
Antifibrinolytic therapy for preventing VWD-related postpartum hemorrhage: indications and limitations.预防血管性血友病（VWD）相关产后出血的抗纤溶治疗：适应证与局限性
Blood Adv. 2017 Apr 25;1(11):699-702. doi: 10.1182/bloodadvances.2017005082.
10
Platelets as immune-sensing cells.血小板作为免疫感知细胞。
Blood Adv. 2016 Nov 22;1(1):10-14. doi: 10.1182/bloodadvances.2016000067. eCollection 2016 Nov 29.
引用本文的文献
1
Contribution of the TIME in BCP-ALL: the basis for novel approaches therapeutics.TIME 在 BCP-ALL 中的作用：开辟新治疗方法的基础。
Front Immunol. 2024 Jan 17;14:1325255. doi: 10.3389/fimmu.2023.1325255. eCollection 2023.
2
Mechanisms of Immune Evasion in Acute Lymphoblastic Leukemia.急性淋巴细胞白血病的免疫逃逸机制
Cancers (Basel). 2021 Mar 26;13(7):1536. doi: 10.3390/cancers13071536.
3
An overview of antibody-drug conjugates in oncological practice.肿瘤学实践中抗体药物偶联物概述。
Ther Adv Med Oncol. 2020 Oct 4;12:1758835920962997. doi: 10.1177/1758835920962997. eCollection 2020.
4
Advances in biology of acute lymphoblastic leukemia (ALL) and therapeutic implications.急性淋巴细胞白血病（ALL）生物学进展及治疗意义
Am J Blood Res. 2018 Dec 10;8(4):29-56. eCollection 2018.
5
An observational study of Chinese adults with relapsed/refractory Philadelphia-negative acute lymphoblastic leukemia.一项针对复发/难治性费城染色体阴性成人急性淋巴细胞白血病中国患者的观察性研究。
Int J Hematol Oncol. 2018 Jul 25;7(2):IJH06. doi: 10.2217/ijh-2018-0006. eCollection 2018 Jun.
本文引用的文献
1
Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study.费城染色体阳性 B 系前体急性淋巴细胞白血病成年患者经blinatumomab 治疗后的完全血液学和分子学缓解：来自 II 期、单臂、多中心研究的结果。
J Clin Oncol. 2017 Jun 1;35(16):1795-1802. doi: 10.1200/JCO.2016.69.3531. Epub 2017 Mar 29.
2
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia.博纳吐单抗对比化疗治疗晚期急性淋巴细胞白血病
N Engl J Med. 2017 Mar 2;376(9):836-847. doi: 10.1056/NEJMoa1609783.
3
Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia.利妥昔单抗在 B 系成人急性淋巴细胞白血病中的应用。
N Engl J Med. 2016 Sep 15;375(11):1044-53. doi: 10.1056/NEJMoa1605085.
4
Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia.奥英妥珠单抗对比标准疗法治疗急性淋巴细胞白血病
N Engl J Med. 2016 Aug 25;375(8):740-53. doi: 10.1056/NEJMoa1509277. Epub 2016 Jun 12.
5
Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial.利妥昔单抗联合剂量密集化疗治疗成人伯基特淋巴瘤：一项随机、对照、开放标签、3 期临床试验。
Lancet. 2016 Jun 11;387(10036):2402-11. doi: 10.1016/S0140-6736(15)01317-3. Epub 2016 Apr 11.
6
The clinical potential of inotuzumab ozogamicin in relapsed and refractory acute lymphocytic leukemia.奥英妥珠单抗在复发难治性急性淋巴细胞白血病中的临床潜力。
Ther Adv Hematol. 2015 Oct;6(5):253-61. doi: 10.1177/2040620715596715.
7
Monoclonal antibodies in acute lymphoblastic leukemia.急性淋巴细胞白血病中的单克隆抗体
Blood. 2015 Jun 25;125(26):4010-6. doi: 10.1182/blood-2014-08-596403. Epub 2015 May 21.
8
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study.Blinatumomab 治疗成人复发/难治性 B 前体急性淋巴细胞白血病患者的安全性和疗效：一项多中心、单臂、2 期研究。
Lancet Oncol. 2015 Jan;16(1):57-66. doi: 10.1016/S1470-2045(14)71170-2. Epub 2014 Dec 16.
9
Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial.利妥昔单抗联合化疗改善成人伯基特淋巴瘤/白血病的预后：一项大型前瞻性多中心试验报告
Blood. 2014 Dec 18;124(26):3870-9. doi: 10.1182/blood-2014-03-563627. Epub 2014 Oct 30.
10
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial.用于治疗儿童和青年急性淋巴细胞白血病的表达CD19嵌合抗原受体的T细胞：一项1期剂量递增试验
Lancet. 2015 Feb 7;385(9967):517-528. doi: 10.1016/S0140-6736(14)61403-3. Epub 2014 Oct 13.
Zotero 插件